Solomon E. Owumi

Postdoctoral Fellow

HIV studies

Glucose transporter-1 (Glut-1), a receptor for human T-cell leukemia virus (HTLV). HTLV, is similar to the human immunodeficiency virus-1 (HIV-1). We have been able to show that Glut-1 (an isotope of the glucose carrier) is up-regulated in PBMC treated with Tat and this is much so evident at 5% oxygen tension (Physiologic oxygen) compared to 20% oxygen tension (normoxic conditions). Glut-1 induction may be a mechanism for viral entry into T-cells in HIV infection and disease pathogenesis.

CD3-expressing human null cells. We are currently trying to identify and phenotype a previously unidentified subset of CD3+ve lymphocytes (null cells) that emerge from CD3-ve population of lymphocytes when treated with Tat. Upon Tat treatment, these 'Null cells" tends to appear after 16-24 hrs and disappears at 48hrs.


Acetaminophen-APAP (Tylenol) studies

High doses of acetaminophen-APAP (Tylenol) induce toxic damage in the liver. We have demonstrated that concurrent oral administration of equimolar APAP and N-acetylcysteine (NAC) to mice mitigates the APAP toxicity at doses up to 600mg/Kg body weight. The prospect of an APAP-NAC formulation that may become available as an OTC drug could reduce the dangers associated with inadvertent overdose with APAP (Tylenol).

Navigation History

People Lab Serge Emaleu